SI9300267A - Novi peptidi, njihova priprava in uporaba za zdravljenje neoplasticnih bolezni - Google Patents

Novi peptidi, njihova priprava in uporaba za zdravljenje neoplasticnih bolezni Download PDF

Info

Publication number
SI9300267A
SI9300267A SI9300267A SI9300267A SI9300267A SI 9300267 A SI9300267 A SI 9300267A SI 9300267 A SI9300267 A SI 9300267A SI 9300267 A SI9300267 A SI 9300267A SI 9300267 A SI9300267 A SI 9300267A
Authority
SI
Slovenia
Prior art keywords
pro
val
xan
alkyl
alkoxy
Prior art date
Application number
SI9300267A
Other languages
English (en)
Slovenian (sl)
Inventor
Andreas Haupt
Franz Emling
Cynthia Romerdahl
Original Assignee
Basf Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Ag filed Critical Basf Ag
Publication of SI9300267A publication Critical patent/SI9300267A/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SI9300267A 1992-05-20 1993-05-20 Novi peptidi, njihova priprava in uporaba za zdravljenje neoplasticnih bolezni SI9300267A (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88578892A 1992-05-20 1992-05-20
US98569692A 1992-11-25 1992-11-25

Publications (1)

Publication Number Publication Date
SI9300267A true SI9300267A (sl) 1993-12-31

Family

ID=27128772

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9300267A SI9300267A (sl) 1992-05-20 1993-05-20 Novi peptidi, njihova priprava in uporaba za zdravljenje neoplasticnih bolezni

Country Status (21)

Country Link
EP (1) EP0642530B1 (de)
JP (2) JP3523253B2 (de)
KR (1) KR100286242B1 (de)
CN (1) CN1065874C (de)
AT (1) ATE169637T1 (de)
AU (1) AU669710B2 (de)
CA (1) CA2136339C (de)
CZ (1) CZ292612B6 (de)
DE (1) DE69320339T2 (de)
DK (1) DK0642530T3 (de)
ES (1) ES2118955T3 (de)
FI (1) FI120692B (de)
HU (2) HUT71398A (de)
IL (1) IL105651A (de)
MX (1) MX9302927A (de)
NO (1) NO310465B1 (de)
NZ (1) NZ252147A (de)
RU (1) RU2116312C1 (de)
SI (1) SI9300267A (de)
UA (1) UA45304C2 (de)
WO (1) WO1993023424A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
DE4415998A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neue Tetrapeptide, ihre Herstellung Verwendung
DE4415997A1 (de) * 1994-05-06 1995-11-09 Basf Ag Neuer peptidischer Wirkstoff und dessen Herstellung
DE19527575A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung von peptidischer Wirkstoffe
DE19527574A1 (de) * 1995-07-28 1997-01-30 Basf Ag Verfahren zur Herstellung vona-(N,N-Dialkyl)-aminocaarbonsäureamiden
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
AU775090B2 (en) * 1995-12-15 2004-07-15 Abbvie Deutschland Gmbh & Co Kg Antineoplastic peptides
US20010009901A1 (en) 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US5741892A (en) * 1996-07-30 1998-04-21 Basf Aktiengesellschaft Pentapeptides as antitumor agents
US5939527A (en) * 1996-07-30 1999-08-17 Basf Aktiengesellschaft Tetrapeptides as antitumor agents
US5965537A (en) * 1997-03-10 1999-10-12 Basf Aktiengesellschaft Dolastatin 15 derivatives with carbonyl and heterocyclic functionalities at the C-terminus
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
EP1049481B1 (de) * 1997-09-24 2005-04-20 Arizona Board Of Regents Synthetische antineoplastische wirkstoffe abgeleitet von dolastatin 15 sowie verfahren zu ihrer herstellung
US6686445B1 (en) 1997-09-24 2004-02-03 Arizona Board Of Regents, Acting For And On Behalf Of Arizona State University Synthetic antineoplastic agents derived from dolastatin 15 and methods of making same
US5985837A (en) * 1998-07-08 1999-11-16 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2004007529A2 (en) * 2002-07-15 2004-01-22 The Trustees Of Princeton University Iap binding compounds
WO2005051372A2 (en) 2003-11-24 2005-06-09 Teva Gyógyszergyár Zártköruen Muködo Részvénytársaság Method of purifying pravastatin
JPWO2023033129A1 (de) 2021-09-03 2023-03-09

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0598129B1 (de) * 1991-08-09 2000-03-22 Teikoku Hormone Mfg. Co., Ltd. Neue tetrapeptidderivate

Also Published As

Publication number Publication date
ES2118955T3 (es) 1998-10-01
CN1065874C (zh) 2001-05-16
DE69320339D1 (de) 1998-09-17
CA2136339A1 (en) 1993-11-25
JPH07506580A (ja) 1995-07-20
FI945416A0 (fi) 1994-11-17
FI120692B (fi) 2010-01-29
IL105651A (en) 1998-07-15
NZ252147A (en) 1996-10-28
KR100286242B1 (ko) 2001-04-16
NO944419D0 (no) 1994-11-18
RU2116312C1 (ru) 1998-07-27
DE69320339T2 (de) 1998-12-17
JP2004149538A (ja) 2004-05-27
IL105651A0 (en) 1993-09-22
CN1085563A (zh) 1994-04-20
HU211745A9 (en) 1995-12-28
WO1993023424A1 (en) 1993-11-25
JP3523253B2 (ja) 2004-04-26
CZ292612B6 (cs) 2003-11-12
DK0642530T3 (da) 1998-10-26
FI945416A (fi) 1994-11-17
NO944419L (no) 1995-01-09
NO310465B1 (no) 2001-07-09
EP0642530B1 (de) 1998-08-12
ATE169637T1 (de) 1998-08-15
HUT71398A (en) 1995-11-28
UA45304C2 (uk) 2002-04-15
CZ284394A3 (en) 1995-05-17
EP0642530A1 (de) 1995-03-15
MX9302927A (es) 1993-11-01
CA2136339C (en) 2008-02-05
AU669710B2 (en) 1996-06-20
RU94046434A (ru) 1996-10-27
AU4066293A (en) 1993-12-13

Similar Documents

Publication Publication Date Title
AU679479B2 (en) Dolostatin analog
EP0832104B1 (de) Derivate von dolastatin, dreen herstellung un verwendung
SI9300267A (sl) Novi peptidi, njihova priprava in uporaba za zdravljenje neoplasticnih bolezni
IL166853A (en) Antineoplastic peptides, their preparation and various uses thereof
PL178351B1 (pl) Nowe peptydy

Legal Events

Date Code Title Description
IF Valid on the event date